Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.18

-2.5%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (16906)	5/23/2005 1:46:50 PM
From: DewDiligence_on_SI	of 52153

Neuro: I agree with much of what you are saying about compliance and reimbursement, but for me those concerns are secondary to the fact that I’m not overly impressed by the outcome data themselves. Why is it impressive that this drug permits a patient to drop from 5 drinks a day to 4 drinks a day three times more often in a month than he was able to do on placebo? IMHO: a big drug company might not even pursue an NDA with tepid data like these, but ALKS has no choice because they’ve made this product their raison d’etre. Regards, Dew

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next